Drug intelligence / Profile preview

XYL-200X

Development stage: Preclinical
Lead developer: Xylo Bio
Modality: Small Molecules

Overview

XYL-200X is a preclinical small-molecule drug candidate developed by Psylo (operating as Xylo Bio). It is designed to target the serotonin 5-HT2A and 5-HT2C receptors. The drug is currently being investigated for the treatment of chronic pain and mood disorders. While the specific functional pharmacology—whether it acts as an agonist, antagonist, or biased ligand—has not been disclosed, the program aims to modulate serotonergic signaling to address unmet needs in neuropsychiatry and pain management.

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on XYL-200X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYL-200X.

Explore the full profile